Tilson L - Search Results

1

Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-Effective.

Kennedy C, McCullagh L, Adams R, Trela-Larsen L, Tilson L, Barry M. Kennedy C, et al. Among authors: tilson l. Value Health. 2021 Oct;24(10):1402-1406. doi: 10.1016/j.jval.2021.03.012. Epub 2021 May 15. Value Health. 2021. PMID: 34593162 Free article.

2

Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010.

Bennett K, Kabir Z, Barry M, Tilson L, Fidan D, Shelley E, Capewell S. Bennett K, et al. Among authors: tilson l. Value Health. 2009 Jan-Feb;12(1):10-5. doi: 10.1111/j.1524-4733.2008.00398.x. Epub 2008 Jul 15. Value Health. 2009. PMID: 19040564 Free article.

3

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

McCullagh L, Tilson L, Walsh C, Barry M. McCullagh L, et al. Among authors: tilson l. Pharmacoeconomics. 2009;27(10):829-46. doi: 10.2165/11313800-000000000-00000. Pharmacoeconomics. 2009. PMID: 19803538

4

Pharmacoeconomic evaluation in Ireland: a review of the process.

Tilson L, O'Leary A, Usher C, Barry M. Tilson L, et al. Pharmacoeconomics. 2010;28(4):307-22. doi: 10.2165/11318790-000000000-00000. Pharmacoeconomics. 2010. PMID: 20222754

5

Public drug expenditure in the Republic of Ireland.

Barry M, Usher C, Tilson L. Barry M, et al. Among authors: tilson l. Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):239-45. doi: 10.1586/erp.10.23. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20545588

6

To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland.

O'Donnell H, Lamrock F, Tilson L, Barry M. O'Donnell H, et al. Among authors: tilson l. Value Health. 2020 Feb;23(2):274-275. doi: 10.1016/j.jval.2019.06.013. Epub 2019 Oct 3. Value Health. 2020. PMID: 32113633 Free article. No abstract available.

7

A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland.

Lamrock F, McCullagh L, Tilson L, Barry M. Lamrock F, et al. Among authors: tilson l. Eur J Health Econ. 2020 Aug;21(6):895-901. doi: 10.1007/s10198-020-01181-0. Epub 2020 Mar 30. Eur J Health Econ. 2020. PMID: 32232603 Free PMC article.

8

Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group.

Leahy J, Hickey C, McConnell D, Cassidy O, Trela-Larsen L, Barry M, Tilson L, McCullagh L; NCPE Review Group. Leahy J, et al. Among authors: tilson l. Value Health. 2020 Nov;23(11):1423-1426. doi: 10.1016/j.jval.2020.09.003. Epub 2020 Oct 5. Value Health. 2020. PMID: 33127011 Free PMC article.

9

The Utility of a Rapid Review Evaluation Process to a National HTA Agency.

Varley Á, Tilson L, Fogarty E, McCullagh L, Barry M. Varley Á, et al. Among authors: tilson l. Pharmacoeconomics. 2022 Feb;40(2):203-214. doi: 10.1007/s40273-021-01093-8. Epub 2021 Oct 12. Pharmacoeconomics. 2022. PMID: 34635994 Free PMC article. Review.

10

Pricing and reimbursement of drugs in Ireland.

Barry M, Tilson L, Ryan M. Barry M, et al. Among authors: tilson l. Eur J Health Econ. 2004 Jun;5(2):190-4. doi: 10.1007/s10198-004-0225-6. Eur J Health Econ. 2004. PMID: 15452757

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

49 results

Search Page